Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.24 -3.1%	$0.27	$0.20 ▼ $1.48	$64.22M	2.24	1.71 million shs	564,916 shs
CGTX Cognition Therapeutics	$0.30 -3.1%	$0.34	$0.22 ▼ $2.54	$18.49M	0.75	2.73 million shs	542,536 shs
GNTA Genenta Science	$3.88 +1.4%	$4.12	$2.79 ▼ $7.28	$70.87M	0.73	15,011 shs	853 shs
SRZN Surrozen	$9.48 +0.9%	$8.93	$5.90 ▼ $18.17	$81.15M	0.57	21,141 shs	16,583 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	-14.38%	-8.46%	-46.19%	-76.70%
CGTX Cognition Therapeutics	0.00%	+1.02%	-5.33%	-33.33%	-87.47%
GNTA Genenta Science	0.00%	-22.65%	-7.96%	+1.04%	+23.02%
SRZN Surrozen	0.00%	+11.53%	+38.39%	-18.21%	-17.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.1391 of 5 stars	4.2	5.0	2.2	0.8	0.0
CGTX Cognition Therapeutics	3.6385 of 5 stars	3.5	5.0	3.0	1.7	1.3
GNTA Genenta Science	2.7534 of 5 stars	3.5	5.0	2.2	1.7	0.0
SRZN Surrozen	3.799 of 5 stars	3.5	3.0	3.8	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	526.63% Upside
CGTX Cognition Therapeutics	3.00	Buy	$5.63	1,785.69% Upside
GNTA Genenta Science	3.00	Buy	$25.00	545.16% Upside
SRZN Surrozen	3.00	Buy	$38.50	306.12% Upside

Current Analyst Ratings Breakdown

Latest CGTX, ADAP, GNTA, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/12/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/2/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/24/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.36	N/A	N/A	$0.17 per share	1.43
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.76 per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.21 per share	N/A
SRZN Surrozen	$11.64M	6.98	N/A	N/A	$18.39 per share	0.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	8/11/2025 (Estimated)
CGTX Cognition Therapeutics	-$25.79M	-$0.74	N/A	N/A	N/A	N/A	-150.93%	-100.82%	8/6/2025 (Estimated)
GNTA Genenta Science	-$12.60M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	-$43.04M	-$24.96	N/A	N/A	N/A	N/A	-120.51%	-54.68%	8/11/2025 (Estimated)

Latest CGTX, ADAP, GNTA, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/9/2025	Q1 2025	SRZN Surrozen	-$1.09	-$3.13	-$2.04	-$7.43	N/A	$0.98 million
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
3/31/2025	Q4 2024	SRZN Surrozen	-$2.54	-$9.10	-$6.56	-$9.10	N/A	$0.66 million
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million
3/20/2025	Q4 2024	CGTX Cognition Therapeutics	-$0.16	-$0.17	-$0.01	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
CGTX Cognition Therapeutics	N/A	2.11	2.11
GNTA Genenta Science	N/A	9.31	N/A
SRZN Surrozen	N/A	7.40	7.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CGTX Cognition Therapeutics	43.35%
GNTA Genenta Science	15.13%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
CGTX Cognition Therapeutics	14.40%
GNTA Genenta Science	28.99%
SRZN Surrozen	45.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	224.05 million	Optionable
CGTX Cognition Therapeutics	20	61.99 million	32.93 million	Not Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable
SRZN Surrozen	80	8.56 million	1.84 million	Not Optionable

CGTX, ADAP, GNTA, and SRZN Headlines

Recent News About These Companies

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Down 16.0% in May

June 3, 2025 | marketbeat.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 2, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares

March 29, 2025 | insidertrades.com

Surrozen to focus Wnt expertise, technologies on ophthalmology programs

March 27, 2025 | markets.businessinsider.com

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

March 26, 2025 | markets.businessinsider.com

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development

March 24, 2025 | quiverquant.com

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

March 24, 2025 | globenewswire.com

Surrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News Summary

January 30, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation

January 30, 2025 | msn.com

H.C. Wainwright sets $32 target on Surrozen stock with Buy rating

January 30, 2025 | msn.com

(SRZN) Trading Advice

January 30, 2025 | news.stocktradersdaily.com

Surrozen initiated with a Buy at H.C. Wainwright

January 30, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, ADAP, GNTA, and SRZN Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.24 -0.01 (-3.08%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.25 +0.01 (+3.18%)

As of 06/13/2025 07:40 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Cognition Therapeutics NASDAQ:CGTX

$0.30 -0.01 (-3.15%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.30 +0.00 (+0.91%)

As of 06/13/2025 07:11 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Genenta Science NASDAQ:GNTA

$3.81 -0.01 (-0.26%)

As of 06/13/2025 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Surrozen NASDAQ:SRZN

$9.48 +0.08 (+0.85%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$9.42 -0.06 (-0.63%)

As of 06/13/2025 04:04 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time